Genetic Diversity of Drug-Related Genes in Native Americans of the Brazilian Amazon

References

• Santos NPC, Ribeiro-Rodrigues EM, Ribeiro-dos-Santos ÂKC, et al. Assessing individual interethnic admixture and population substructure using a 48-insertion-deletion (INSEL) ancestry-informative marker (AIM) panel. Hum Mutat. 2010;31(2):184–190. doi:10.1002/humu.21159
   PubMed Web of Science ®Google Scholar
• Comissão de Integração Nacional, Desenvolvimento Regional e da Amazônia. Available from: www2.camara.leg.br/atividade-legislativa/comissoes/comissoes-permanentes/cindra/amazonia-legal/mais-informacoes-sobre-a-amazonia-legal. Accessed April 15, 2020.
   Google Scholar
• Instituto Brasileiro de Geografia e Estatística (IBGE). No Title. Available from: https://indigenas.ibge.gov.br/images/pdf/indigenas/folder_indigenas_web.pdf. Accessed September 27, 2020.
   Google Scholar
• Carlos EA, Ricardo Ventura Santos ALE. Epidemiologia e Saúde Dos Povos Indígenas No Brasil. Editora Fiocruz; 2003.
   Google Scholar
• Suarez-Kurtz G. Pharmacogenetics in the Brazilian population. Front Pharmacol. 2010;1:118. doi:10.3389/fphar.2010.00118
   Web of Science ®Google Scholar
• Suarez-Kurtz G, Paula DP, Struchiner CJ. Pharmacogenomic implications of population admixture: brazil as a model case. Pharmacogenomics. 2014;15(2):209–219. doi:10.2217/pgs.13.238
   PubMed Web of Science ®Google Scholar
• Whirl-Carrillo M, McDonagh EM, Hebert JM, et al. Pharmacogenomics knowledge for personalized medicine. Clin Pharmacol Ther. 2012;92(4):414–417. doi:10.1038/clpt.2012.96
   PubMed Web of Science ®Google Scholar
• Auton A, Abecasis GR, Altshuler DM, et al. A global reference for human genetic variation. Nature. 2015;526(7571):68–74. doi:10.1038/nature15393
   PubMed Web of Science ®Google Scholar
• The pharmacogenomics knowledgebase. PharmGK. Available from: https://www.pharmgkb.org/. Accessed December 30, 2020.
   Google Scholar
• U.S. Department of Health and Human Services FaDA. Available from: http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ucm073162.pdf. Accessed September 27, 2020.
   Google Scholar
• de Ramos BRA, MPB D, Amador MAT, et al. Neither self-reported ethnicity nor declared family origin are reliable indicators of genomic ancestry. Genetica. 2016;144(3):259–265. doi:10.1007/s10709-016-9894-1
   Web of Science ®Google Scholar
• Jombart T, Devillard S, Balloux F. Discriminant analysis of principal components: A new method for the analysis of genetically structured populations. BMC Genet. 2010;11:11. doi:10.1186/1471-2156-11-94
   Web of Science ®Google Scholar
• González JR, Armengol L, Solé X, et al. SNPassoc: an R package to perform whole genome association studies. Bioinformatics. 2007;23(5):644–645. doi:10.1093/bioinformatics/btm025
   PubMed Web of Science ®Google Scholar
• Aulchenko YS, Ripke S, Isaacs A, van Duijn CM. GenABEL: an R library for genome-wide association analysis. Bioinformatics. 2007;23(10):1294–1296. doi:10.1093/bioinformatics/btm108
   PubMed Web of Science ®Google Scholar
• Hartshorne T, Scientific TF, Le F, et al. A high-throughput real-time pcr approach to pharmacogenomics studies. J Pharmacogenomics amp. 2013;05. doi:10.4172/2153-0645.1000133
   Google Scholar
• Gaedigk A, Simon SD, Pearce RE, Bradford LD, Kennedy MJ, Leeder JS. The CYP2D6 activity score: translating genotype information into a qualitative measure of phenotype. Clin Pharmacol Ther. 2008;83(2). doi:10.1038/sj.clpt.6100406
   Web of Science ®Google Scholar
• Gaedigk A, Sangkuhl K, Whirl-Carrillo M, Klein T, Steven Leeder J. Prediction of CYP2D6 phenotype from genotype across world populations. Genet Med. 2017;19(1):69–76. doi:10.1038/gim.2016.80
   PubMed Web of Science ®Google Scholar
• Kuhn PC, Horimoto ARVR, Sanches JM, Vieira Filho JPB, Franco L, Fabbro AD. Genome-wide analysis in Brazilian Xavante Indians reveals low degree of admixture. PLoS One. 2012;7(8):e42702. doi:10.1371/journal.pone.0042702
   Web of Science ®Google Scholar
• Salzano FM, Sans M. Interethnic admixture and the evolution of Latin American populations. Genetics Molecular Biol. 2014;37(1 suppl 1):151–170. doi:10.1590/s1415-47572014000200003
   Web of Science ®Google Scholar
• Mizzi C, Dalabira E, Kumuthini J, Dzimiri N, Balogh I, Başak NA. European spectrum of pharmacogenomic biomarkers: implications for clinical pharmacogenomics. PLoS One. 2016;11(9):e0162866. doi:10.1371/journal.pone.0162866
   PubMed Web of Science ®Google Scholar
• Jittikoon J, Mahasirimongkol S, Charoenyingwattana A, Chaikledkaew U, Tragulpiankit P, Mangmool S. Comparison of genetic variation in drug ADME-related genes in Thais with Caucasian, African and Asian HapMap populations. J Hum Genet. 2016;61(2):119–127. doi:10.1038/jhg.2015.115
   PubMed Web of Science ®Google Scholar
• Rodrigues JCG, Fernandes MR, Guerreiro JF, Ribeiro-dos-Santos  C, Santos S. Polymorphisms of ADME-related genes and their implications for drug safety and efficacy in Amazonian Amerindians. Sci Rep. 2019;9(1):7201. doi:10.1038/s41598-019-43610-y
   Web of Science ®Google Scholar
• Cuautle-Rodríguez P, Llerena A, Molina-Guarneros J. Present status and perspective of pharmacogenetics in Mexico. Drug Metabol Drug Interact. 2014;29(1):37–45. doi:10.1515/dmdi-2013-0019
   Google Scholar
• Chiurillo MA, Griman P, Santiago L, Torres K, Moran Y, Borjas L. Distribution of GSTM1, GSTT1, GSTP1 and TP53 disease-associated gene variants in native and urban Venezuelan populations. Gene. 2013;531(1):106–111. doi:10.1016/j.gene.2013.08.055
   Web of Science ®Google Scholar
• Rito T, Vieira D, Silva M, Conde-Sousa E, Pereira L, Mellars P. A dispersal of Homo sapiens from southern to eastern Africa immediately preceded the out-of-Africa migration. Sci Rep. 2019;9(1):4728. doi:10.1038/s41598-019-41176-3.
   Web of Science ®Google Scholar
• Bryc K, Durand EY, Macpherson JM, Reich D, Mountain JL. The genetic ancestry of african americans, latinos, and european Americans across the United States. Am J Hum Genet. 2015;96(1):37. doi:10.1016/j.ajhg.2014.11.010
   Web of Science ®Google Scholar
• Céspedes-Garro C, Naranjo MEG, Ramírez R, Serrano V, Fariñas H, Barrantes R. Pharmacogenetics in Central american healthy volunteers: interethnic variability. Drug Metab Pers Ther. 2015;30(1):19–31. doi:10.1515/dmdi-2014-0025
   Google Scholar
• Shriner D, Tekola-Ayele F, Adeyemo A, Rotimi CN. Ancient human migration after out-of-Africa. Sci Rep. 2016;6:26565. doi:10.1038/srep26565
   Web of Science ®Google Scholar
• DM RR, DQB V, Crovella S, Brandão LAC. On the use of Chinese population as a proxy of Amerindian ancestors in genetic admixture studies with Latin American populations. Eur J Hum Genet. 2016;24:326–327. doi:10.1038/ejhg.2015.184
   Web of Science ®Google Scholar
• Sosa-Macías M, Lazalde-Ramos BP, Galaviz-Hernández C, Rangel-Villalobos H, Salazar-Flores J, Martínez-Sevilla VM. Influence of admixture components on CYP2C9*2 allele frequency in eight indigenous populations from Northwest Mexico. Pharmacogenomics J. 2013;13(6):567–572. doi:10.1038/tpj.2012.52
   PubMed Web of Science ®Google Scholar
• Food and Drug Administration. Table of Pharmacogenomics Biomarkers in Drug Labeling. Available from: https://www.fda.gov/drugs/science-and-research-drugs/table-pharmacogenomic-biomarkers-drug-labeling. Accessed September 27, 2020.
   Google Scholar
• Horstmann S, Lucae S, Menke A, Hennings JM, Ising M, Roeske D. Polymorphisms in GRIK4, HTR2A, and FKBP5 show interactive effects in predicting remission to antidepressant treatment. Neuropsychopharmacology. 2010;35(3):727–740. doi:10.1038/npp.2009.180
   Web of Science ®Google Scholar
• Matic M, De Wildt SN, Tibboel D, Van Schaik RHN. Analgesia and opioids: a pharmacogenetics shortlist for implementation in clinical practice. Clin Chem. 2017;63(7):1204–1213. doi:10.1373/clinchem.2016.264986
   PubMed Web of Science ®Google Scholar
• Baber M, Bapat P, Nichol G, Koren G. The pharmacogenetics of opioid therapy in the management of postpartum pain: a systematic review. Pharmacogenomics. 2016;17(1):75–93. doi:10.2217/pgs.15.157
   Web of Science ®Google Scholar
• Chuah B, Goh BC, Lee SC, et al. Comparison of the pharmacokinetics and pharmacodynamics of S-1 between Caucasian and East Asian patients. Cancer Sci. 2011;102(2):478–483. doi:10.1111/j.1349-7006.2010.01793.x
   PubMed Web of Science ®Google Scholar
• Alachkar H, Fulton N, Sanford B, Malnassy G, Mutonga M, Larson RA. Expression and polymorphism (rs4880) of mitochondrial superoxide dismutase (SOD2) and asparaginase induced hepatotoxicity in adult patients with acute lymphoblastic leukemia. Pharmacogenomics J. 2017;17(3):274–279. doi:10.1038/tpj.2016.7
   PubMed Web of Science ®Google Scholar
• Chan SL, Samaranayake N, Ross CJD, Toh MT, Carleton B, Hayden MR. Genetic diversity of variants involved in drug response and metabolism in Sri Lankan populations: implications for clinical implementation of pharmacogenomics. Pharmacogenet Genomics. 2016;26(1):28–39. doi:10.1097/FPC.0000000000000182
   Web of Science ®Google Scholar
• Sun X, Yu WY, Le MW, Huang LH, Yang GP. Impact of the CYP4F2 gene polymorphisms on the warfarin maintenance dose: A systematic review and meta-analysis. Biomed Reports. 2016;4(4):498–506. doi:10.3892/br.2016.599
   Google Scholar
• Shendre A, Brown TM, Liu N, Hill CE, Beasley TM, Nickerson DA. Race-specific influence of CYP4F2 on dose and risk of hemorrhage among warfarin users. Pharmacotherapy. 2016;36(3):263–272. doi:10.1002/phar.1717
   Web of Science ®Google Scholar
• LLerena A, Naranjo MEG, Rodrigues-Soares F, Penas-LLedó EM, Fariñas H, Tarazona-Santos E. Interethnic variability of CYP2D6 alleles and of predicted and measured metabolic phenotypes across world populations. Expert Opin Drug Metab Toxicol. 2014;10(11):1569–1583. doi:10.1517/17425255.2014.964204
   PubMed Web of Science ®Google Scholar
• Lazalde-Ramos BP, Martínez-Fierro MDLL, Galaviz-Hernández C, Garza-Veloz I, Naranjo MEG, Sosa-Macías M. CYP2D6 gene polymorphisms and predicted phenotypes in eight indigenous groups from northwestern Mexico. Pharmacogenomics. 2014;15(3):339–348. doi:10.2217/pgs.13.203
   Web of Science ®Google Scholar
• Fricke-Galindo I, Jung-Cook H, Llerena A, López-López M. Interethnic variability of pharmacogenetic biomarkers in mexican healthy volunteers: a report from the RIBEF (Ibero-American Network of Pharmacogenetics and Pharmacogenomics. Drug Metab Pers Ther. 2016;31(2):61–81. doi:10.1515/dmpt-2015-0030
   Google Scholar
• Gaedigk A, Dinh JC, Jeong H, Prasad B, Leeder JS. Ten years’ experience with the CYP2D6 activity score: a perspective on future investigations to improve clinical predictions for precision therapeutics. J Pers Med. 2018;8(2):15. doi:10.3390/jpm8020015
   Web of Science ®Google Scholar
• Perez-Paramo YX, Hernandez-Cabrera F, Rojas-Martinez A, Ortiz-Lopez R. CYP2D6 in amerindians from southern mexico: low variability and higher frequency of functional alleles. Drug Metab Pers Ther. 2015;30(4):231–238. doi:10.1515/dmpt-2015-0017
   Google Scholar
• Moreno N, Flores-Angulo C, Villegas C, Mora Y. CYP2D6 variability in populations from venezuela. Drug Metab Pers Ther. 2016;31(4):181–189. doi:10.1515/dmpt-2016-0023
   Google Scholar
• Chen GL, Liu F-Q, Yang L. The P450 oxidoreductase (POR) rs2868177 and cytochrome P450 (CYP) 2B6*6 polymorphisms contribute to the interindividual variability in human CYP2B6 activity. Eur J Clin Pharmacol. 2016;72(10):1205–1213. doi:10.1007/s00228-016-2095-0
   Web of Science ®Google Scholar
• Queiroz MAF, Laurentino RV, da Silva Graça Amoras E. The CYP2B6 G516T polymorphism influences CD4+ T-cell counts in HIV-positive patients receiving antiretroviral therapy in an ethnically diverse region of the Amazon. Int J Infect Dis. 2017;55:4–10. doi:10.1016/j.ijid.2016.12.002
   Web of Science ®Google Scholar
• Amstutz U, Henricks LM, Offer SM, Barbarino J, Schellens JHM, Swen JJ. Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for dihydropyrimidine dehydrogenase genotype and fluoropyrimidine dosing: 2017 update. Clin Pharmacol Ther. 2018;103(2):210–216. doi:10.1002/cpt.911
   PubMed Web of Science ®Google Scholar
• Henricks LM, Lunenburg CATC, Man FM, Meulendijks D, Frederix GWJ, Kienhuis E. DPYD genotype-guided dose individualisation of fluoropyrimidine therapy in patients with cancer: a prospective safety analysis. Lancet Oncol. 2018;19(11):1459–1467. doi:10.1016/S1470-2045(18)30686-7.
   PubMed Web of Science ®Google Scholar
• Gentile G, Botticelli A, Lionetto L, Mazzuca F, Simmaco M, Marchetti P. Genotype-phenotype correlations in 5-fluorouracil metabolism: A candidate DPYD haplotype to improve toxicity prediction. Pharmacogenomics J. 2016;16(4):320–325. doi:10.1038/tpj.2015.56
   PubMed Web of Science ®Google Scholar
• Hesselink DA, Bouamar R, Elens L, Van Schaik RHN, Van Gelder T. The role of pharmacogenetics in the disposition of and response to tacrolimus in solid organ transplantation. Clin Pharmacokinet Clin Pharmacokinet. 2014;53:123–139. doi:10.1007/s40262-013-0120-3
   PubMed Web of Science ®Google Scholar
• Rodrigues-Soares F, Suarez-Kurtz G. Pharmacogenomics research and clinical implementation in Brazil. Basic Clin Pharmacol Toxicol. 2019;124(5):538–549. doi:10.1111/bcpt.13196
   PubMed Web of Science ®Google Scholar
• Galaviz-Hernández C, Lazalde-Ramos BP, Lares-Assef I, et al. Influence of genetic admixture components on CYP3A5*3 Allele-associated hypertension in amerindian populations from northwest mexico. Front Pharmacol. 2020:11. 10.3389/fphar.2020.00638.
   Web of Science ®Google Scholar
• Birdwell KA, Decker B, Barbarino JM, et al. Clinical Pharmacogenetics Implementation Consortium (CPIC) guidelines for CYP3A5 genotype and tacrolimus dosing. Clin Pharmacol Ther. 2015;98(1):19–24. doi:10.1002/cpt.113
   PubMed Web of Science ®Google Scholar
• Santoro A, Felipe CR, Tedesco-Silva H, Medina-Pestana JO, Struchiner CJ, Ojopi EB. Pharmacogenetics of calcineurin inhibitors in Brazilian renal transplant patients. Pharmacogenomics. 2011;12(9):1293–1303. doi:10.2217/pgs.11.70
   PubMed Web of Science ®Google Scholar
• Tonk ECM, Gurwitz D, Maitland-van der Zee A-H, Janssens ACJW. Assessment of pharmacogenetic tests: presenting measures of clinical validity and potential population impact in association studies. Pharmacogenomics J. 2017;17(4):386–392. doi:10.1038/tpj.2016.34
   PubMed Web of Science ®Google Scholar
• Ramsey LB, Johnson SG, Caudle KE, Haidar CE, Voora D, Wilke RA. The clinical pharmacogenetics implementation consortium guideline for SLCO1B1 and Simvastatin-Induced Myopathy: 2014 Update. Clin Pharmacol Ther. 2014;96(4):423–428. doi:10.1038/clpt.2014.125
   PubMed Web of Science ®Google Scholar
• Linskey DW, English JD, Perry DA, et al. Association of SLCO1B1 c.521T>C (rs4149056) with discontinuation of atorvastatin due to statin-associated muscle symptoms. Pharmacogenet Genomics. 2020:22. 10.1097/FPC.0000000000000412.
   Web of Science ®Google Scholar